| Literature DB >> 30760514 |
Fang Zhu1,2, Jason Chui1, Ian Herrick1, Janet Martin1,2,3.
Abstract
OBJECTIVES: We aim to evaluate the diagnostic test accuracy (DTA) of intraoperative evoked potential (EP) monitoring to detect cerebral injury during clipping of cerebral aneurysms.Entities:
Keywords: cerebral aneurysm; cerebral injury; evoked potential monitoring; ischemia; motor evoked potential; stroke
Mesh:
Year: 2019 PMID: 30760514 PMCID: PMC6377512 DOI: 10.1136/bmjopen-2018-022810
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Definitions of positive and negative events in the best-case/worst-case scenario approaches for the analysis of diagnostic test accuracy
| Index test (significant EP changes) | |||||
| Yes | No | ||||
| Reversible EP changes | Irreversible EP changes | ||||
| Conservative approach (worst-case) | Reference test* | Yes | TP | FN | |
| No | FP | TN | |||
| Liberal approach (best-case) | Yes | FN | TP | FN | |
| No | TP | FP | TN | ||
*Either new-onset postoperative neurological deficits or radiological changes. The definition(s) for liberal approach calculation are as follows:
True-positives were defined as either: (a) A significant intraoperative EP signal change that is irreversible in spite of all rescue intervention(s) employed, and followed by a new-onset postoperative neurological deficit or radiological change. (b) A significant intraoperative EP signal change that is reported to be reversed by an intraoperative rescue intervention and not followed by a new postoperative neurological deficit or radiological change. All reports of reversal of the EP signal change(s) were assumed to reflect mitigation of injury as a consequence of the intervention.
False-positives were defined as no new postoperative neurological deficit or radiological change despite irreversible intraoperative EP signal changes indicating potential neurological injury that were not reversed to baseline by surgical or anaesthetic rescue intervention(s).
True-negatives were defined as no significant intraoperative EP signal changes accompanied by no new postoperative neurological deficits or radiological changes.
False-negatives were defined as a reported new postoperative neurological deficit or radiological change associated with: (a) No significant intraoperative EP signal change. (b) Significant EP signal changes that were reversed to baseline following intraoperative surgical or anaesthetic rescue intervention.
EP, evoked potential; FN, false negative; FP, false positive; TP, true positive, TN, true negative.
Study characteristics
| Study ID | Study design | Consecutive series of patients | Study period | No. of patients studied (n) | No. of patients analysed (n) | No. of procedure (n) | Country | Follow-up time |
| Kashkoush | Retro | Yes | 2006–2013 | 267 | 177 | 117 | USA | Postoperative within 3 days |
| Staarmann | Retro | Yes | January 2010–April 2014 | 123 | 133 | 133 | USA | Postoperative till discharge |
| Kim | Retro | Yes | January 2013–December 2014 | 726 | 685 | NR | Korea | Postoperative till discharge |
| Takebayashi | Pro | NR | January 2006–December 2011 | 50 | 50 | 50 | Japan | Postoperative and at discharge |
| Yue | Pro | Yes | January 2009–August 2011 | 44 (MEP+SSEP) | 43 | 44 | China | Postoperative, at discharge, 3 months and 1 year after discharge (up to 30.3–33.5 months) |
| Sasaki | Pro | Yes | September 2009– April 2013 | 270 (177 MEP, 75 SSEP, 33 VEP) | 177 | 285 | Japan | Postoperative |
| Kang | Unclear | NR | NR | 47 | 45 (SSEP), 37 (MEP) | NR | China | Postoperative day 7 |
| Wicks | Retro | Yes | January 1991–December 2009 | 663 | 663 | 691 | USA | At discharge, and within 2 years after discharge |
| Maruta | Pro | Yes | NR | 22 | 18 | NR | Japan | Postoperative, at discharge |
| Ni | Pro | Yes | December 2009– February 2011 | 23 | 23 | 23 | China | Postoperative till discharge |
| Motoyama | Retro | NR | April 2007–November 2009 | 48 | 48 | 48 | Japan | Postoperative |
| Krayenbuhl | Pro | NR | December 2005–March 2007 | 36 | 36 | 51 | Switzerland | Postoperative 2 days |
| Lin | Retro | Yes | January–August 2010 | 45 | 45 | NR | China | Postoperative, postoperative 1 week, at discharge |
| Yeon | Pro | Yes | January 2007–December 2008 | 164 | 98 | 98 | Korea | Postoperative, postoperative 1 day, and at discharge |
| Irie | Retro | No | Sepember 2003– March 2009 | 111 | 111 | NR | Japan | Postoperative, and on further symptoms |
| Szelényl | Retro and Pro | No | NR | 318 | 108 | NR | USA and Germany | Postoperative, at discharge and 6 months after discharge |
| Penchet | Retro | NR | 1995–2002 | 122 | 122 | 120 | France | Postoperative within 48 hours, and at 1 month |
| Szelényl | Retro and Pro | Yes | NR | 119 | 113 | 148 | Germany | Postoperative 1 day, and 1 week |
| Schick | Others | NR | NR | 76 | 76 | 79 | Germany | Postoperative, 1 week and 2 weeks |
| Horiuchi | Pro | No | NR | 53 | 53 | 55 | Japan | Postoperative |
| Neuloh and Schramm | Pro | Yes | NR | 95 | 95 (SSEP); 81 (MEP) | 100 | China | Postoperative, at discharge, at postoperative 3 months |
| Suzuki | Pro | Yes | January 1997–February 2002 | 108 | 108 | 108 | Japan | Postoperative |
| Min | Pro | NR | NR | 87 | 60 | 60 | China | Postoperative, and >3 months after surgery |
| Holland | Pro | NR | 1996 | 45 | 45 | 45 | USA | Postoperative |
| Sako | Unclear | No | NR | 15 | 15 | 15 | Japan | Postoperative, at 3 months |
| Sako | Pro | Yes | September 1992– October 1993 | 25 | 25 | 26 | China | Postoperative |
| Manninen | Others | No | 1985–1991 | 67 | 67 | 70 | Japan | Postoperative with 24 hours, at discharge |
| Mizoi and Yoshimoto | Pro | Yes | July 1986–June 1989 | 97 | 97 | 97 | Japan | Postoperative |
| Lazorthes | Unclear | NR | March 1991–September 1991 | 30 | 30 | NR | China | Postoperative within 48 hours, at 6 months after discharge |
| Matsuda | Pro | NR | NR | 49 | 49 | 55 | Korea | Postoperative 1–2 days |
| Manninen | Pro | NR | NR | 157 | 97 | 174 | Japan | Immediately postoperative, at discharge |
| Schramm | Pro | NR | NR | 102 | 94 | 113 | USA and Germany | Early, later and late postoperative |
| Buchthal | Pro | NR | NR | 25 | 25 | 25 | France | NR |
| Momma | Pro | NR | NR | 40 | 40 | 40 | Germany | Postoperative, and postoperative 6 months |
| Kidooka | Pro | NR | NR | 28 | 31 | 31 | Japan | Postoperative and >2 weeks |
*Repeated procedures on the same patient in some studies. The number of procedure was reported.
†Duplicate publication found.
EP, evoked potential; MEP, motor evoked potential; NR, not reported; Pro, prospective cohort; Retro, retrospective cohort; SSEP, somatosensory evoked potential.
Summary of events
| Study ID | No. of patients requiring temporary clipping, n (%) | Mean duration of temporary clipping (min) | Neuroprotection strategy | Intraoperative manoeuvres to treat cerebral ischaemia | No. of cases with clinical neurological deficit, n (%) | No. of radiographic strokes, | Total no. of cases with EP changes, n (%)* | No. of cases with irreversible changes, n (%)* | No. of cases with reversible changes, n (%) | No. of cases with partial changes, n (%) |
| Kashkoush 2017 | 177 | 11.7 | NR | NR | 10 (6) | NR | 29 (16) | NR | NR | NR |
| Staarmann 2017 | 123 | NR | PBS (propofol) | NR | 3 (2) | 2 (2) | 15 (11) | 3 (20) | 12 (80) | 0 (0) |
| Kim 2016 | NR | NR | NR | Hyperventilation | 36 (5) | NR | 43 (6.3) | 13 (30) | 30 (70) | Included in irreversible cases. |
| Takebayashi 2014 | NR | NR | NR | NR | 10 (20) | 17 (34) | 19 (38) | 4 (21) | 15 (79) | NR |
| Yue 2014 | NR | NR | NR | ROSC, RR | 8 (20) | 7 (16) | 15 (17) | 1 (7) | 14 (93) | NR |
| Sasaki 2014 | NR | NR | NR | ROSC | 6 (3) | NR | 22 (8) | 2 (9) | 20 (91) | NR |
| Kang 2013 | NR | NR | 20% mannitol | NR | SSEP: 3 (8) | NR | SSEP: 12 (27); MEP; 8 (19) | NR | NR | NR |
| Wicks 2012 | NR | NR | PBS (propofol), PH | ROSC | 2 (11) | NR | 45 (7) | 18 (40) | 27 (60) | 0 (0) |
| Maruta 2012 | NR | NR | NR | NR | 6 (26) | NR | 5 (23) | NR | NR | NR |
| Ni 2012 | NR | 12.4±4.7 | PBS | ROSC | 1 (2) | NR | 6 (26) | 1 (17) | 5 (83) | NR |
| Motoyama 2011 | 15 (31) | 4.6 | NR | NR | NR | 5 (10) | 5 (10) | 1 (20) | 4 (80) | NR |
| Krayenbuhl 2011 | NR | 5.8 | NR | ROSC | 3 (7) | NR | 5 (14) | NR | NR | NR |
| Lin 2011 | 16 (36) | 5.3±3.3 | NR | Others | NR | 8 (8) | 12 (27) | 0 (0) | 10 (80) | 2 (20) |
| Yeon 2010 | 98 (60) | NR | PBS (thiopentione) | NR | 3 (3) | 7 (7) | 12 (12) | NR | NR | NR |
| Irie 2010 | NR | NR | NR | NR | dc-MEP: 4 (4) | NR | 6 (6) | 1 (17) | 5 (83) | NR |
| Szelényl 2007 | NR | NR | NR | NR | NR | 15 (11) | 14 (12) | 9 (64) | 5 (36) | NR |
| Penchet 2007 | 118 (97) | 3m25s | NR | ROSC | 17 (15) | NR | 34 (26) | 2 (6) | 25 (74) | 7 (21) |
| Szelényl 2006 | 71 (60) | 5–11.8 | NR | ROSC | NR | 28 (35) | 14 (12) | 4 (27) | 10 (73) | NR |
| Schick 2005 | 37 (49) | 8.1 | PBS (methohexital), PH | ROSC, RR, ABP | SSEP: 4 (8) | SSEP: 2 (4) | 19 (25) | 2 (11) | 6 (32) | 11 (58) |
| Horiuchi 2005 | NR | NR | NR | NR | MEP: 11 (12) | NR | 10 (19) | 1 (10) | 9 (90) | 0 (0) |
| Neuloh and Schramm 2004 | NR | NR | NR | Others | 5 (5) | 2 (2) | SSEP: 7 | NR | NR | NR |
| Suzuki 2003 | NR | NR | NR | NR | 9 (15) | NR | 20 (19) | 1 (5) | 19 (95) | 0 (0) |
| Min 2001 | NR | 10.2±5.7 | PBS (thiopenton), BPA | ABP | NR | 7 (16) | 14 (16) | NR | NR | NR |
| Holland 1998 | 27 (60) | NR | PBS (propofol) | NR | 3 (20) | NR | 8 (18) | 2 (25) | 6 (75) | 0 (0) |
| Sako 1998 | 15 (100) | 17.2 | 20% Mannitol | NR | 2 (8) | NR | 9 (60) | 0 (0) | 9 (100) | NR |
| Sako 1995 | NR | NR | 20% Mannitol | NR | 19 (24) | NR | 12 (48) | 2 (17) | 10 (83) | NR |
| Manninen 1994 | NR | NR | NR | ROSC, RR | 8 (8) | NR | SSEP: 14 (20) | SSEP: 3 (21) | SSEP: 11 (79) | NR |
| Mizoi and Yoshimoto | 97 (100) | 17.9 | NR | NR | 10 (33) | NR | 42 (43) | 3 (7) | 39 (93) | NR |
| Lazorthes 1992 | 18 (60) | 2–39 | NR | NR | 12 (22) | NR | 20 (67) | 9 (45) | 11 (55) | NR |
| Matsuda 1991 | NR | NR | NR | NR | 23 (24) | NR | 15 (27) | NR | NR | NR |
| Manninen 1990 | 97 (62) | NR | NR | NR | 20 (35) | NR | 23 (15) | 8 (35) | 15 (65) | 0 (0) |
| Schramm 1990 | 22 (22) | NR | BPA | Others | 4 (16) | NR | 16 (18) | 1 (12) | 15 (88) | 0 (0) |
| Buchthal 1988 | 25 (100) | 6.3–52 | PH | NR | 12 (30) | NR | 9 (36) | NR | NR | NR |
| Momma 1987 | 40 (100) | 1–69 | NR | NR | 12 (43) | NR | 21 (53) | 21 (100) | 0 (0) | 0 (0) |
| Kidooka 1987 | 15 (54) | NR | PH | NR | 10 (6) | NR | 13 (46) | NR | NR | NR |
*The total numbers of cases with EP changes are based on the numbers of cases (not events) reported in the primary studies. The total numbers include allintraoperative EP monitoring modalities used in the primary study (if data are available); however, this may vary across different studies.
†Repeated procedures on the same patient in some studies. The number of procedure was reported.
‡One patient with unreliable SSEP was excluded in the analysis.
BAEP, brain-stem auditory evoked potential monitoring; BPA, blood pressure augmentation; dc-MEP, direct cortical-motor evoked potential; EP, evoked potential; MEP, motor evoked potential; NR, not reported; PBS, pharmacological burst suppression; PH, passive hypothermia; RR, retractor reposition; ROSC, removal of surgical clip; SSEP, somatosensory evoked potential; tc-MEP, transcranial-motor evoked potential.
Figure 1Forest plot of somatosensory evoked potential for predicting postoperative neurological deficit.
Summary of results
| Test | n | TP | FP | FN | TN | Sensitivity | Specificity | LR+ | LR− | PPV | NPV |
| Postoperative neurological deficits (clinical stroke) | |||||||||||
| SSEP | 17 | 104 | 193 | 111 | 1368 | 0.59 (0.39 to 0.76) | 0.86 (0.77 to 0.92) | 4.17 (2.26 to 7.68) | 0.48 (0.3 to 0.78) | 0.35 | 0.92 |
| MEP | 14 | 75 | 131 | 38 | 1518 | 0.81 (0.58 to 0.93) | 0.9 (0.86 to 0.93) | 8.19 (5.78 to 11.6) | 0.21 (0.09 to 0.52) | 0.36 | 0.98 |
| tc-MEP | 9 | 39 | 84 | 32 | 1222 | 0.58 (0.44 to 0.71) | 0.92 (0.87 to 0.95) | 6.81 (4.37 to 10.6) | 0.46 (0.34 to 0.63) | 0.32 | 0.97 |
| dc-MEP | 5 | 22 | 45 | 2 | 294 | 0.98 (0.1 to 1) | 0.87 (0.82 to 0.9) | 7.3 (5.4 to 9.87) | 0.02 (0 to 8.78) | 0.33 | 0.99 |
| BAEP | 1 | 8 | 7 | 11 | 54 | 0.42 (0.20 to 0.67) | 0.89 (0.78 to 0.95) | 3.67 | 0.65 | 0.53 | 0.83 |
| SSEP+MEP | 3 | 11 | 22 | 1 | 167 | 0.92 (0.62 to 1.00) | 0.88 (0.83 to 0.93) | 7.88 (5.13 to 12.08) | 0.09 (0.01 to 0.62) | 0.33 | 0.99 |
| SSEP+BAEP | 1 | 16 | 13 | 3 | 48 | 0.84 (0.60 to 0.97) | 0.79 (0.66 to 0.88) | 3.95 | 0.2 | 0.55 | 0.94 |
| Postoperative radiological features of stroke | |||||||||||
| SSEP | 6 | 34 | 51 | 25 | 383 | 0.55 (0.39 to 0.7) | 0.89 (0.84 to 0.93) | 5.1 (3.33 to 7.8) | 0.51 (0.36 to 0.72) | 0.4 | 0.94 |
| MEP | 9 | 43 | 71 | 25 | 601 | 0.63 (0.51 to 0.74) | 0.9 (0.81 to 0.95) | 6.23 (3.23 to 12.05) | 0.41 (0.3 to 0.56) | 0.38 | 0.96 |
BAEP, brainstem auditory evoked potential; dc-MEP, direct cortical-motor evoked potential; FP, false positive; FN, false negative; LR+, positive likelihood ratio; LR−, negative likelihood ratio; NPV, negative predictive value; PPV, positive predictive value; SSEP, somatosensory evoked potential; tc-MEP, transcortical-motor evoked potential; TP, true positive; TN, true negative.
Figure 2Forest plot of motor evoked potential for predicting postoperative neurological deficit.
Summary of estimated ranges of DTA in predicting postoperative neurological deficit using a best-case scenario and worst-case scenario approach
| Evoked potential monitoring | No. of study | No. of patients | Best-case scenario DTA estimates | Worst-case scenario DTA estimates | ||
| Sn | Sp | Sn | Sp | |||
| SSEP | 10 | 1262 | 63 (49 to 75) | 100 (91 to 100) | 50 (30 to 69) | 81 (66 to 90) |
| MEP | 5 | 1152 | 74 (55 to 87) | 100 (90 to 100) | 59 (41 to 76) | 93 (89 to 95) |
| SSEP and MEP | 3 | 201 | 94 (80 to 99) | 100 (98 to 100) | 89 (52 to 100) | 83 (71 to 92) |
DTA, diagnostic test accuracy; MEP, motor evoked potential; Sn, sensitivity; Sp, specificity; SSEP, somatosensory evoked potential.